From: Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey
Disease | No. of patients | Clinical response (available data) | Median treatment duration (days) (IQR) | Associated * treatment | CCS | DMARDs | Still treated | Associated treatment reduction | ||
---|---|---|---|---|---|---|---|---|---|---|
None | Partial | Total | Â | Â | Â | Â | Â | |||
AOSD | 35 | 3 (8.6%) | 12 (34.3%) | 19 (54.3%) | 461 (1164) | 28/34 (82.4%) | 24/28 (85.7%) | 26/28 (92.9%) | 15/35 (42.9%) | 25/34 (73.5%) |
Gout | 28 | 0 | 6 (21.4%) | 22 (78.6%) | 7 (96.5) | 20/27 (74.1%) | 7/20 (35%) | 0 | 3/24 (12.5%) | 22/24 (91.7%) |
sJIA | 26 | 3 (11.5%) | 12 (46.2%) | 11 (42.3%) | 502 (1154) | 22/23 (95.7%) | 20/22 (90.1%) | 9/22 (40.9%) | 10/26 (38.5%) | 22/25 (88%) |
CAPS | 21 | 0 | 6 (28.6%) | 15 (72.4%) | 1059 (1235) | 7/18 (38.9%) | 3/8 | 2/9 | 10/21 (47.6%) | 11/13 |
FMF | 13 | 1 (7.6%) | 6 (46.2%) | 6 (46.2%) | 390 (814.5) | 10/12 (83.3%) | 4/12 (33.3%) | 2/12 (16.7%) | 7/13 (53.8) | 6/9 (66.7%) |
MKD | 10 | 0 | 7 (70.0%) | 3 (30.0%) | 266 (448) | 3/4 | 1/4 | 0/4 | 3/10 | 3/3 |
SAPHO | 9 | 4 (44.4%) | 4 (44.4%) | 1 (11.1%) | 86 (337) | 4/8 | 1/4 | 1/4 | 2/9 | 3/6 |
Schnitzler’s syndrome | 7 | 1 (16.7%) | 0 | 5 (83.3%) | 479 (1227) | 4 (/5) | 2/4 | 1/4 | 4/7 | 5/6 |
Spondyloarthritis | 5 | 4 | 1 | 0 | 30 (10–91) | 3/5 | 1/5 | 0/5 | 0/5 | 3/5 |
Vasculitis | 4 | 0 | 2 | 1 | 424 (94–916) | 3/3 | 3/3 | 1/3 | 2/4 | 3/3 |
Chondro calcinosis | 4 | 1 | 2 | 1 | 52 (6–227) | 2/4 | 1/4 | 1/4 | 2/4 | 2/4 |
GPP | 3 | 0 | 0 | 3 | 56 (6–129) | 2/3 | 1/3 | 0/3 | 1/3 | 2/3 |
Polychondritis | 3 | 0 | 2 | 1 | 395 (110–1961) | 3/3 | 3/3 | 3/3 | 1/3 | 2/3 |
TRAPS | 3 | 0 | 2 | 1 | 215 (29–225) | 3/3 | 3/3 | 0/3 | 2/3 | 2/3 |
NAPS12 | 2 | 0 | 2 | 0 | 797 | 2/2 | 0/2 | 0/2 | 0/2 | 0/2 |